Source:http://linkedlifedata.com/resource/pubmed/id/16740728
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
11
|
pubmed:dateCreated |
2006-6-2
|
pubmed:abstractText |
Restricted and high-level expression of interleukin-13 receptor alpha2 (IL-13Ralpha2) in a majority of human malignant gliomas makes this protein an attractive vaccine target. We have previously described the identification of the IL-13Ralpha2(345-353) peptide as a human leukocyte antigen-A2 (HLA-A2)-restricted CTL epitope. However, as it remains unclear how efficiently peptide-based vaccines can induce specific CTLs in patients with malignant gliomas, we have examined whether analogue epitopes could elicit heteroclitic antitumor T-cell responses versus wild-type peptides. We have created three IL-13Ralpha2 analogue peptides by substitutions of the COOH-terminal isoleucine (I) for valine (V) and the NH(2)-terminal tryptophan (W) for either alanine (A), glutamic acid (E), or nonsubstituted (W; designated as 1A9V, 1E9V, and 9V, respectively). In comparison with the native IL-13Ralpha2 epitope, the analogue peptides 9V and 1A9V displayed higher levels of binding affinity and stability in HLA-A2 complexes and yielded an improved stimulatory index for patient-derived, specific CTLs against the native epitope expressed by HLA-A2(+) glioma cells. In HLA-A2-transgenic HHD mice, immunization with the peptides 9V and 1A9V induced enhanced levels of CTL reactivity and protective immunity against an intracranial challenge with IL13Ralpha2-expressing syngeneic tumors when compared with vaccines containing the native IL-13Ralpha2 epitope. These findings indicate highly immunogenic IL-13Ralpha2 peptide analogues may be useful for the development of vaccines capable of effectively expanding IL-13Ralpha2-specific, tumor-reactive CTLs in glioma patients.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A2 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/IL13RA1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Il13ra1 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-13 Receptor alpha1...,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Interleukin-13
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0008-5472
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
66
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
5883-91
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:16740728-Animals,
pubmed-meshheading:16740728-CD8-Positive T-Lymphocytes,
pubmed-meshheading:16740728-Cancer Vaccines,
pubmed-meshheading:16740728-Cell Line, Tumor,
pubmed-meshheading:16740728-Glioma,
pubmed-meshheading:16740728-HLA-A2 Antigen,
pubmed-meshheading:16740728-Humans,
pubmed-meshheading:16740728-Interleukin-13 Receptor alpha1 Subunit,
pubmed-meshheading:16740728-Lymphocyte Activation,
pubmed-meshheading:16740728-Mice,
pubmed-meshheading:16740728-Mice, Transgenic,
pubmed-meshheading:16740728-Peptide Fragments,
pubmed-meshheading:16740728-Receptors, Interleukin,
pubmed-meshheading:16740728-Receptors, Interleukin-13,
pubmed-meshheading:16740728-T-Lymphocytes, Cytotoxic
|
pubmed:year |
2006
|
pubmed:articleTitle |
Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.
|
pubmed:affiliation |
Department of Neurological Surgery, University of Pittsburgh School of Medicine, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Research Support, N.I.H., Extramural
|